Galera Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 59.08 million compared to USD 62.22 million a year ago. Basic loss per share from continuing operations was USD 1.33 compared to USD 2.3 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.094 USD | -2.08% | -13.76% | -35.35% |
Jun. 07 | Galera Therapeutics, Inc. Eliminates Robert A. Beardsley as Chief Operating Officer | CI |
Jun. 06 | Galera Therapeutics, Inc.(OTCPK:GRTX) dropped from S&P TMI Index | CI |
1st Jan change | Capi. | |
---|---|---|
-35.35% | 5.11M | |
+18.15% | 124B | |
+18.02% | 112B | |
+3.78% | 22.94B | |
-12.75% | 22.22B | |
-9.86% | 17.02B | |
-16.36% | 16.88B | |
-39.94% | 16.87B | |
+2.80% | 13.63B | |
+27.39% | 11.61B |
- Stock Market
- Equities
- GRTX Stock
- News Galera Therapeutics, Inc.
- Galera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023